Meeting Report
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
Presented by Narjust Florez (Duma), MD, and Stephanie McDonald, NP
From Dana-Farber Cancer Institute, Boston, Massachusetts
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2023;14(3):241–247 |
https://doi.org/10.6004/jadpro.2023.14.3.12 |
© 2023 Harborside™
ABSTRACT
The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non–small cell lung cancer.
For access to the full length article, please
sign in.
